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Abstract
Background: Tuberculosis (TB), particularly multi- and or extensive drug resistant TB, is still a global medical
emergency. Whole genome sequencing (WGS) is a current alternative to the WHO-approved probe-based methods
for TB diagnosis and detection of drug resistance, genetic diversity and transmission dynamics of Mycobacterium
tuberculosis complex (MTBC). This study compared WGS and clinical data in participants with TB.
Results: This cohort study performed WGS on 87 from MTBC DNA isolates, 57 (66%) and 30 (34%) patients with
drug resistant and susceptible TB, respectively. Drug resistance was determined by Xpert® MTB/RIF assay and
phenotypic culture-based drug-susceptibility-testing (DST). WGS and bioinformatics data that predict phenotypic
resistance to anti-TB drugs were compared with participant’s clinical outcomes. They were 47 female participants
(54%) and the median age was 35 years (IQR): 29–44). Twenty (23%) and 26 (30%) of participants had TB/HIV co-
infection BMI < 18 kg/m2 respectively. MDR-TB participants had MTBC with multiple mutant genes, compared to
those with mono or polyresistant TB, and the majority belonged to lineage 3 Central Asian Strain (CAS). Also, MDR-
TB was associated with delayed culture-conversion (median: IQR (83: 60–180 vs. 51:30–66) days). WGS had high
concordance with both culture-based DST and Xpert® MTB/RIF assay in detecting drug resistance (kappa = 1.00).
Conclusion: This study offers comparison of mutations detected by Xpert and WGS with phenotypic DST of
M. tuberculosis isolates in Tanzania. The high concordance between the different methods and further insights
provided by WGS such as PZA-DST, which is not routinely performed in most resource-limited-settings, provides an
avenue for inclusion of WGS into diagnostic matrix of TB including drug-resistant TB.
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Background
Tuberculosis (TB), caused by the Mycobacterium tuber-
culosis complex (MTBC), is the leading cause of mortal-
ity, killing about 2 million people each year globally [1].
The highest TB mortality and morbidity occurs in low
and middle income countries like Tanzania [1, 2]. HIV
infection is the most important single predictor of TB
incidence across the African continent [3]. This is crit-
ical because HIV/AIDS is likely to increase in the risk of
progression TB infection by 30 times, due to impairment
on the immune system [3]. Sub-Saharan Africa carries a
disproportionate burden of HIV, accounting for more
than 70% of the global burden of infection [4]. For in-
stance, in 2017, nearly 2.5 million people who contracted
TB lived in sub-Saharan Africa, and 665,000 of them
died from the disease [5]. The recent introduction of the
Xpert®MTB/Rif assay (Cepheid, USA) has shown an
increase in detection of drug resistance TB patients and
the detection of multidrug-resistant TB (MDRTB) has
increased three- to eight-fold compared to conventional
testing [6]. Despite the gaps in documentation of MDR-
TB cases in several Sub-Saharan African countries
(SSA), pooled analysis that involved several studies re-
ported a prevalence of 2.1% of MDR-TB in new cases,
signifying a low prevalence of MDR-TB cases in SSA [7].
The relatively low prevalence of MDRTB in SSA might
be attributed by the recent introduction of rifampicin in
Africa, by the use of rifampicin-free treatment regimens
in the continuation phase (during months three to
eight), by the growing use of directly observed treatment
as recommended under the directly observed treatment,
short course (DOTS) strategy, and by the use of fixed-
dose combination tablets in a few countries [8, 9].
Tanzania is among African countries south of Sahara
with the highest burdens of TB, with an estimated 295
TB cases per 100,000 adults. The National anti-
tuberculosis drug resistance survey conducted in 2010 in
Tanzania found the resistance to any of the four first-
line drugs in new patients to be 8.3%, while the preva-
lence of MDR-TB was 1.1%. However, the crude preva-
lence for any resistance and for MDR-TB in retreated
cases increased to 20.6 and 3.9% respectively [10].
The emergence of resistant strains of MTBC to anti-
tuberculosis drugs like rifampicin (RIF), isoniazid (INH),
pyrazinamide (PZA), ethambutol (EMB), streptomycin
(SM) among others; and the emergence of HIV in the
1980s led to resurgence of TB [11]. Multidrug resistant
TB (MDR-TB), defined as resistance to at least RIF and
INH, is usually caused by MTBC strains that harbour
mutations in rpoB, katG and inhA genes associated with
RIF and INH resistance. Globally, MDR-TB claims over
580,000people’s lives annually [12]. About 10% of MDR-
TB isolates exhibit resistance to fluoroquinolones (FQs)
and second-line-injectable drugs (SLIDs) (aminoglycosides/
cyclic-polypeptides), referred to as extensive drug resistant
TB (XDR-TB), which challenges clinical management [2,
13, 14]. Patients with XDR-TB are infected with MTBC
that have mutations in rrs, tlyA or eis promoter region (SLI
related) and gyrA or gyrB genes (FQ related). Clinical man-
agement of both MDR-TB and XDR-TB is very complex
and there are different treatment regimens [15]. About 50
and 70% of patients treated for MDR-TB and XDR-TB
have unfavourable treatment outcomes, respectively.
Although XDR-TB is rare in Tanzania, cohort review re-
ports of patients treated for MDR-TB show that treatment
success is only 75%. However, control and prevention mea-
sures should be strengthened in the country to reduce
MDRTB related morbidity and mortality. To improve treat-
ment outcomes and control escalation of MDR/XDR-TB;
early, rapid and accurate diagnostic methods are required
to detect and decipher susceptibility profile of the MTBC
to anti-TB drugs in TB endemic settings such as Tanzania.
As in other TB endemic settings, Tanzania has de-
ployed rapid molecular methods for dual detection of
MTBC and susceptibility to either RIF alone or along
with INH and second-line injectable and fluoroquino-
lones. For example, while the Xpert®MTB/Rif assay
(Cepheid, USA) detects MTBC and provides informa-
tion about susceptibility to RIF only [16], the geno-
type MTBDRplus and MTBDRsl assays (Hain Life
sciences, Germany) detect mutations that are strongly
associated with multiple types of MDR-TB and also
XDR-TB respectively [17, 18]. These assays have po-
tential to guide implementation of the new WHO
shorter regimen for treating MDR-TB [15, 19]. Unlike
Whole genome sequencing (WGS), these PCR-probe
based assays have limited anti-TB drug-susceptibility
value especially if mutations occur outside the target
region [20]. In recent years, WGS platforms have be-
come an alternative diagnostic in addressing probe-
based assay limitations. WGS can identify genotypes
predictive of drug-resistance phenotype within the en-
tire region of microbial genome and has potential to
determine genetic relatedness and identify transmis-
sion dynamics necessary in guiding clinical decisions.
There is a need to sequence as many MTBC strains
as possible, build libraries of single nucleotide poly-
morphisms (SNPs) and other variants, compare the
relatedness of MTBC strains, and correlate variation
with clinical progress or outcomes as a whole. Based
on this, we performed WGS for the first time on
isolates sourced from patients treated for MDR-TB at
Kibong’oto Infectious Diseases Hospital (KIDH) in
Tanzania. These data will provide a baseline set of
the types and variations in TB in Tanzania. Clinical
and laboratory information such as treatment regi-
men, phenotypic susceptibility profile, prior history of
treatment with first line anti-TB drugs, HIV status,
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culture conversion rate and treatment outcomes were
available for analysis.
Results
Baseline demographic and clinical characteristics of study
participants
A total of87study participants with positive MTBC cul-
ture results were included in the genetic study of whom,
47 (54%) were females. The median age was 35 (Inter-
quartile range = 29–44) years (Table 1). Twenty (23%)
were co-infected with HIV and had a median CD4
counts of 246 (IQR =119–388) cells/mm3.
Association of clinical information with genetic drug
resistance
Table 2 summarizes demographic and clinical character-
istics of TB patients. We found association between
previous history of TB treatment and phenotypic drug
resistance (OR, 0.01 95% CI: 0.0003–0.0995, p = < 0.001)
(Table 2).
Analysis of mutations associated with phenotypic drug
resistance to anti-TB drugs
Of the 87 MTBC isolates sequenced, 57 (65.5%) had at
least one mutation in a gene that was predictive for 7
anti-drugs (Table 3). The concordance between pheno-
typic DST and WGS was 97% for RIF (DST: WGS; 26:28
isolates), 81% INH (DST: WGS; 40:51 isolates) and 95%
for SM (DST: WGS; 8:11 isolates) (kappa = 1.00).
Moreover, the concordance between Xpert® MTB/RIF
(Cepheid, USA) and WGS for detection of RIF resistance
was 95% (8:11 isolates) (kappa = 1.00). Substitution of
serine to threonine at codon 315 (S315T) of the katG
gene accounted for 50 (94.3%) of mutations (Table 3).
The common mutation associated with phenotypic
resistant to RIF was S450L (substitution of serine to
leucine) accounted for 96% (26/27) of the detected RIF
resistance. Of the 57 isolates, 29 (33%) had mutations in
the embB gene and Q497R was the common mutation
(8/29; 27.6%) (Table 3). Nineteen isolates had mutations,
in pncA genes of which V128G was the common
accounting for 7 (36.8%) (Table 3). In addition, our
analysis revealed pncA deletion involving Rv2044c in
two drug resistance isolates (MDRTB & polyresistance
isolates) that contributed 5.3% (1 isolates) of MDRTB
and other resistance pattern (Table 3). Patients with
MDR-TB had highly diverse mutations as compared to
monoresistance (Table 3). We found 2 pre patients har-
bouring XDRTB isolates. The drug resistance mutations
involving either rrs or gyrB genes against AMK and FQs
respectively were detected in low proportions among DR
resistance isolates (Table 3). These isolates had mutation
either at the rrs gene involving substitution of C to T at
codon 51 (C517T) or gyrB gene which involved replace-
ment of R by C at codon 446 (R446C). MTBC isolates
from drug susceptible patients had no mutations in
genes encoding for INH, RFP, PZE, STM and EMB.
Treatment outcome and culture conversion rates among
the drug resistance TB isolates
Of the 57 study participants with mutation (s) to at least
one of the anti-TB drugs, 47 (82.5%) had successful
treatment, 3 (5.3%) died, and 7 (12.3%) defaulted
(Table 4). Three patients (2MDR-TB and 1 with polyre-
sistant) died 9 months after enrolment, during which
they were in a continuous phase of anti-mycobacterial
medications. The median (IQR) culture conversion rates
were 51 (30–66) days and 83 (60–180) days for partici-
pants with mono/polyresistant and MDR/XDR-TB,
respectively (Table 4).
Phylogenetic analysis of the drug resistance TB isolates
Phylogenetic analysis revealed that the DR-TB strains
were heterogeneously distributed in lineages 1 to 7
(Fig. 1). The Central Asian Strains (CAS) (lineage 3) pre-
dominated in the MTBC strains and accounted for
48.3% (42/87) of the isolates, followed by lineage 4 (32/
87; 36.8%), lineage 1 (10/87; 11.5%), lineage 2 (3/87;
3.4%) and 1 (1.1%). Of the 24 MDR isolates, 15 (62.5%)
Table 1 Demographic and clinical information of study
participants
Variable N %
Gender
Male 40 46
Female 47 54
Age category (years)
< 33 31 35.6
≥ 33 56 64.4
HIV status
Negative 67 77
Positive 20 23
Diabetic
Yes 1 1.2
No 86 98.8
Previous history of TB treatment
New 45 51.7
Retreatment 42 48.3
CD4 count (n = 20)
< 200 8 40
≥200 12 60
Body mass index
< 16–18.5 26 29.9
≥ 18.5 61 70.1
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isolates belonged to lineage 3 (CAS), 5 (20.8%) isolates
were lineage 4 (Latin American Mediterranean, LAM), 2
(8.3%) isolates were lineage 2 and 2 (8.3%) isolates
originated from lineage 1 (East African Indian, EAI)
(Table 5).
Discussion
In this study, we found high concordance between WGS
and conventional culture-based DST in predicting
phenotypic drug resistance to anti-TB drugs, ranging
from 81% for INH to 97% for RIF, and 95% concordance
with Xpert® MTB/RIF (Cepheid, USA) for RIF. These
findings are in agreements with those previously
reported in different TB endemic settings [21–24]. The
ability of Xpert® MTB/RIF and phenotypic detection of
TB drug resistance cannot be underscored as it can pave
a way to complementary and confirmatory WGS in early
detection of resistance. Studies have shown phenotypic
susceptibility tests to serve as reference standards [25],
and that both Xpert assay and DST can provide informa-
tion on polyresistance in pre- XDR-TB [26] despite
varying sensitivities [27, 28].
The current practice in diagnosing drug resistant tu-
berculosis is through the WHO-approved probe-based
assays like Xpert® MTB/RIF (Cepheid, USA) for RIF [16]
and either genotype MTBDRplus for RIF and INH or
genotype MTBDRsl (Hain Lifesciences, Germany) for
aminoglycosides/capreomycin and fluoroquinolones that
must be confirmed with culture-based DST [29]. Unlike
WGS, these assays not only have limited DST range to
identify hot-spot resistant determining regions but they
also cannot inform transmission dynamics [30, 31]. The
high concordance supports adoption of WGS as an
alternative diagnostic tool to complement results from
DST of all previously treated presumptive or confirmed
rifampicin resistance cases in clinical settings. Although
the facilities are not yet available the approach can be
advocated in future clinical settings to enable reduction
in unnecessary laboratory diagnostic time delays be-
tween identification of patients suspected of MDR-TB
and initiation of treatment [29]. The potential for WGS
to provide a rapid and comprehensive view of the geno-
type and reliable prediction of the drug susceptibility
phenotype has been reported elsewhere [23, 32, 33]. This
is an important platform to inform about susceptibility
profile drugs like pyrazinamide (PZA), which is pre-
scribed empirically in Tanzania and other resource
limited countries. PZA kills semi-dormant bacilli and
has synergetic activity with bedaquiline (BDQ), a key
core drug in the currently recommended all-oral inject-
able free MDR-TB regimen(s). This synergism supports
design of a shortened treatment regimens, which favours
healthy patient outcomes [34].
In our study, the WGS uncovered 2 pre patient har-
bouring XDR-TB isolates, which were also detected by
phenotypic DST at our hospital and later cured after
MDR-TB treatment. This finding adds value to WGS as
a potential molecular tool to complement phenotypic-
DST and other molecular assay such Gene Xpert® MTB/
RIF (Cepheid, USA) MDR-TB results for informed
Table 2 Demographic and clinical characteristics of drug resistance TB patients
Variables, n (%) DR-TB (n = 57) DS-TB (n = 30) OR (95% C.I) for DR-TB p values
Gender
Male 26 14 o.96 (0.36–2.56) 0.93
Female 31 16
Age (years)
< 33 21 10
≥ 33 36 20 1.17 (0.42–3.34) 0.55
HIV status
Negative 41 26 2.5 (0.70–11.47) 0.12
Positive 16 4
CD4 count (n = 20)
< 200 6 2
≥ 200 10 2 0.6 (0.04–10.62) 0.65
Previous history of TB treatment
New 16 29 0.01 (0.0003–0.0995) <0.001
Retreatment 41 1
Body mass index
< 16–18.5 19 7
≥ 18.5 38 23 1.6 (0.55–5.34) 0.33
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decision-making prior to anti-tuberculosis therapy. For
effective use particularly in low- and middle-income
countries, WGS must be robust, easy to use, and
affordable.
We also found that the majority of the MTBC isolates
from DR-TB participants had mutations in genes predict-
ive of phenotypic resistance to all 7 anti-TB drugs tested
including INH (katG), RIF (rpoB), EMB (embB, embC-
embA), FQs (gyrB) and second line injectable drugs (rrs)
(Table 3). The commonest mutations found in this study
was S450L for rpoB (26/27), S315T on katG (51/56),
Q497R (8/29) and G406S (5/29) on embB, C16T (5/29) on
embC-embA, V128G (7/19) on pncA and K43R on rpsL
genes are in keeping with findings reported elsewhere [35,
36]. As expected, patients with MDR-TB had multiple
mutations in these genes, confirming the previous concept
that drug resistance in mycobacteria spp., and other bac-
teria evolves as they accumulate mutations either de novo
or after multiple and longer exposure to antibiotics [37,
38]. This high diversity of mutations among DR-TB pa-
tients suggests on-going transmission of MDR-TB strains
rather than acquisition through random mutation and se-
lection of drug resistance strains [37, 39]. In addition, our
analysis revealed a large deletion that involved Rv2044c in
Table 3 Frequency and distribution of mutations associated with drug resistance M. tuberculosis
Drug Target gene mutation n (%) in monoresistance n (%) in MDR-TB strains n (%) in other resistance pattern Total (N)
RIF (n = 27) rpoB S450L 4 (14.8) 16 (59.3) 6 (22.2) 26
D435Y 1 (3.7) 1 (3.7) – 1
INH (n = 55) katG S315T 10 (18.2) 24 (43.6) 16 (29.1) 50
S302R – 1 (1.8) 1 (1.8) 2
N138S – 1 (1.8) – 1
oxyR’-ahpC C52T – 1 (1.8) – 1
C54T – 1 (1.8) – 1
EMB (n = 29) embB Y319C – – 1 (3.4) 1
Q497R – 6 (20.9) 2 (6.9) 8
G406D – – 1 (3.4) 1
G406S – 2 (6.9) 3 (10.3) 5
M306L – 1 (3.4) – 1
M306I – 1 (3.4) – 1
G406A – 3 (10.3) – 3
M306V – 2 (6.9) – 2
Y334H – 1 (3.4) – 1
M306T – 1 (3.4) – 1
EmbC-embA C16T 1 1 (3.4) 3 (10.3) 5
PZA (n = 19) pncA V128G – 8 (42.1) – 8
A193AT – – 1 (5.3) 1
G17D – – 1 (5.3) 1
D8N 1 – – 1
L85P – – 1 (5.3) 1
A46V – 1 (5.3) – 1
P69L – 1 (5.3) – 1
Q10R – 1 (5.3) – 1
D49G – 1 (5.3) – 1
D63A – 1 (5.3) – 1
Rv2044c – 1 (5.3) 1 (5.3) 2
STR (n = 3) rpsL K43R – 2 (100) – 2
rrs C517T – 1 (100) – 1
FLO (n = 1) gyrB R446C – 1 (100) – 1
AMK (n = 2) rrs C517T – 2 (100) – 2
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the PZA resistance isolates. Such isolates also possessed
mutations either in drug resistance genes for RIF or INH.
INH, FQS and SLIDs are used for shorter MDR-TB treat-
ment regimes. However, mutations involving genes associ-
ated with INH, EMB, FQs and SLIDs resistance affect the
selection of appropriate treatment regimens [15, 19]. INH
and EMB have been in use for several decades either as
part of the standard treatment regimen for drug suscep-
tible TB and INH monotherapy as infection preventive
therapy for HIV infected individuals [40]. On the other
hand, MTBC isolates from DS-TB participants had no
mutations in genes encoding for INH, RIF, PZA, SM and
EMB, which is in keeping with Cryptic consortium find-
ings that reported susceptibility profiles for all isolates un-
less uncharacterized mutations or missing key nucleotide
calls were present [41]. We found 2 pre-XDR-TB patients
possessing R446C and C517Tmutations in the gyrB and
rrs genes, in addition S315T, S450L, G406A and C517T
mutations in the katG, rpoB, embB and rrs genes respect-
ively. At this juncture, it is worthwhile to translate these
Fig. 1 Phylogenetic tree showing relationship of M. tuberculosis drug resistance strains, and pattern of drug resistance
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Table 5 Description of lineages, spoligotype, cluster of drug resistance M. tuberculosis and genotype at important drug loci
Isolate
ID
Lineages Spoligotype WGS
cluster
Genotype at drug loci
RIF ZN AMK PZ FLR AMG EMB ST
rpoB katG rrs pncA gyrB rrs embB embC-
embA
rpsL_ rrs
1 lineage3 CAS MDR S450L S315T Large deletion
pncA Rv2044c
7 lineage3 CAS MDR S450L S315T
11 lineage4 LAM DR D8N
20 lineage4 LAM DR D435Y
38 lineage3 CAS MDR S450L N138S M306V,
Q497R,
G406A
42 lineage3 CAS DR S315T
51 lineage4 LAM DR S315T
52 lineage1 EAI DR S315T Y319C
63 lineage3 CAS MDR S450L S315T M306I
71 lineage3 CAS DR S315T G17D Q497R
75 lineage3 CAS DR S315T G406D
81 lineage4 LAM DR S315T L85P G406S,
M306I
82 lineage3 CAS MDR S450L S315T V128G M306L
85 lineage3 CAS MDR S450L S315T C517T C517T G406A C517T
92 lineage4 LAM DR S315T Q497R,
G406S
98 lineage4 LAM DR S315T
104 lineage4 LAM DR S315T
106 lineage4 LAM MDR S450L S315T Q10R
110 lineage4 LAM DR S315T
111 lineage4 LAM DR S315T
115 lineage4 LAM DR S315T, S302R
130 lineage
4
LAM MDR S450L S315T
143 lineage
4
LAM DR S315T C16T
144 lineage
4
CAS MDR S450L S315T
146 lineage
3
CAS MDR S450L S315T V128G
151 lineage
3
CAS MDR S450L S315T V128G Q497R
100-
S17
lineage
3
CAS MDR S450L S315T V128G Q497R
101-
S16
lineage
4
LAM MDR S450L S315T, S302R D49G Q497R
113-
S15
lineage
4
LAM DR S315T
114-
S19
lineage
4
LAM MDR S450L S315T D63A
132_
S10
lineage
4
LAM DR S315T
134_ lineage CAS MDR S450L S315T G406S
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mutations into clinical practice and investigate their asso-
ciation with participant’s health outcomes. In this study,
participants with MDR-TB were cured using the
recommended treatment regimen and reverted late to cul-
ture negativity as compared to those with mono- or poly-
resistance (Table 4). Time to culture conversion was
Table 5 Description of lineages, spoligotype, cluster of drug resistance M. tuberculosis and genotype at important drug loci
(Continued)
Isolate
ID
Lineages Spoligotype WGS
cluster
Genotype at drug loci
RIF ZN AMK PZ FLR AMG EMB ST
rpoB katG rrs pncA gyrB rrs embB embC-
embA
rpsL_ rrs
S8 3
137-
S22
lineage2 Beijing MDR S450L S315T R446C
139-
S17
lineage
1
EAI DR
140-
S21
lineage1 EAI DR OxyR-ahpC, C52T,
large deletion, S315T
A193AT
141-S1 lineage
4
LAM DR S315T Large, deletion,
pncA-Rv2044c
145-
S11
lineage
2
Beijing MDR S450L S315T P69L M306T,
G406A
K43R
17-S14 lineage
4
LAM DR S315T
301-
S24
lineage
3
CAS MDR S450L S315T C517T A46V C517T M306G,
G406S
342-
S10
lineage
3
CAS DR S315T G406S
43-S19 lineage4 LAM DR S315T
44-S20 lineage
3
CAS DR S315T
50-S18 lineage
3
CAS MDR S450L S315T V128G Y334H, C16T
56-S6 lineage
4
LAM DR S315T
60-S3 lineage
4
LAM DR S450L
73-S5 lineage3 CAS DR S450L
78-S15 lineage4 LAM DR S315T
79-S12 lineage4 LAM DR S315T C16T
80-S3 lineage3 CAS DR M306I C16T
89-S18 lineage4 LAM MDR S450L S315T
90-S23 lineage
3
CAS MDR S450L S315T V128G Q497R,
M306V
91-S8 lineage
3
CAS MDR S450L S315T V128G, Q497R
94-S14 lineage
3
CAS MDR S450L S315T
96-S11 lineage1 EAI MDR S450L S315T
99-S4 lineage
4
LAM DR S315T
S23 lineage DR S315T C16T K43R
S9 lineage
3
CAS DR S315T
RIF Rifampicin, INH Isoniazid, AMK Amikacin, PZ Pyrazinamide, FLR Fluoroquinolones, AMG Aminoglycosides, EMB Ethambutol, ST Streptomycin
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highly prolonged to more than 6months in participants
with pre-XDR-TB, who had multiple mutations. Delayed
time to culture conversion in our study is similar to find-
ings by Sangita et al., [42] and Shibabaw et al., [43] in
India and Ethiopia who documented reversion time to
culture negativity after 125 and 77 days of treatment re-
spectively. In addition, the spectrum of mutations to genes
that predict phenotypic resistance to anti-TB drugs deter-
mines treatment outcomes. Fortunately, 82.5% (47/57) of
study participants achieved treatment success, similar to
findings by Meressa et al., [44] in Ethiopia. This success
rate is 30% higher than the global MDR-TB treatment
success rate [15], positioning the WGS method along with
culture based DST as a useful testing algorithm for rigor-
ous microbiological monitoring that will accelerate the
2035 strategic END-TB vision to create a world popula-
tion free of TB [45]. Over 17% of study participants had
unfavourable treatment outcomes (5% mortality and 12%
lost-to- follow-up), similar to that reported by Meressa
et al. [44],. However, this is lower than that reported by
Dheda et al., [46] and Milanov et al., [47] in South Africa
and Bulgaria who both documented over 50% unfavour-
able treatment outcomes. Previous findings have argued
that severe malnutrition (BMI < 16 kg/m2), HIV co-
infection, previous history of anti-TB therapy and drug ad-
verse events can predict poor treatment outcomes [47,
48]. In this study, 29.9% of the study participants had low
BMI and 23% were infected with HIV but had no effects
on MDR-TB treatment outcomes.
In our study, the phylogenetic analysis showed distinct
DR-TB spoligotype lineages similar to a previous finding
by Kidenya et al. [49] in North-western Tanzania who
reported strain variation across different spoligotype-
defined M. tuberculosis lineages. We found that, the
Central Asian strains (CAS) genotype (lineage 3) were
the predominant lineages (Table 5), with no evidence of
any change in terms of the CAS dominance over the
past few years in Tanzania [50]. The CAS is among the
prevalent lineage in the Indian subcontinent, South-East
Asia, the Middle-East and East-Africa [51], showing a
North-South divide along the Tropic of Cancer in the
Eastern hemisphere – mainly in Asia, and partly pro-
longed along the horn of Africa [51, 52]. The dominance
of CAS lineages in our local settings might be attributed
to early contact due to migration and trade between
people in Asian and East Africa countries. The seem-
ingly prolonged stable dominance of CAS lineage reflects
limited movement in of new infections from other
sources/origins to influence the constantly circulating
strains.
The main strength of our study is that we have corre-
lated and linked WGS with treatment response and out-
comes in a resource limited clinical TB endemic setting
like Tanzania, which was not available previously. WGS
provides high resolution when investigating diseases
transmission in outbreaks, provides results for 2nd line
drugs which is currently not performed in our settings.
In addition to that, the WGS enables earlier use of the
most appropriate drug regimen, thus improving patient
outcomes and reducing overall healthcare costs [33].
This is the first step to start thinking how this technol-
ogy could be included and add value in the future DR-
TB diagnosis cascade, in high burden areas with limited
resources where the need for rapid and accurate tools
for assisting clinical decision making for optimal patient
care and in predicting the treatment outcomes is very
high.
However, our study has some limitations. Phenotypic
culture-based DST for PZA, and cycloserine, which were
part of the standardized treatment regimen for all partic-
ipants was missing. In addition, concordance between
line probe assays (LPA) genotype MDBTDRplus and
MTBDRsl and WGS could not be done, which would
have given a full comparison of the robustness of the
WGS since the former had not been in use at the time
of the study. In addition, WGS was performed retro-
spectively on clinical isolates, genetic data was not ap-
plied in the real time in the clinical setting, and hence
no treatment regimen was modified to favour outcomes.
Moreover, the use of WGS on frozen isolates of M. tu-
berculosis does not allow us to make considerations and
comparisons between Xpert®MTB/Rif assay, phenotypic
DST and WGS. Finally, WGS provides rapid and com-
prehensive diagnosis of DR-TB and the WHO has recog-
nized its great potential for rapidly diagnosing drug-
resistant TB in diverse clinical settings. However, there
are challenges that need to be overcome prior to the im-
plementation of whole-genome sequencing in resource-
limited countries. These include high cost of equipment,
the requirement for technical training, the need for ex-
pert guidance on the clinical interpretation of WGS data
as the kind of information provided from the previous
typing methods, the lack of simple solutions to obtain
genome sequencing information directly from sputum
samples and how it can be accommodated into our pre-
existing diagnostic frameworks. Nevertheless, the useful
information presented in this study outweighs these lim-
itations and can be used to advocate for a policy change
in the adoption of molecular TB diagnostic algorithms.
Conclusion
WGS uncovered mutations in genes that predict pheno-
typic resistance to anti-TB drugs, signifying its import-
ance in informed decision making prior to anti
tuberculosis therapy. Expectedly, WGS was robust in
ruling out DR-TB especially in absence of detectable
mutations, which was the case in drug susceptible M. tu-
berculosis clinical isolates. The WGS-based DST best
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correlated with culture conversion rates and treatment
outcome, indicating its potential application in designing
an optimally individualized treatment regimen for
favourable treatment outcomes in TB endemic settings.
Methods
Study settings
This study was conducted at Kibong’oto Infectious dis-
eases hospital (KIDH) in Siha District, Kilimanjaro re-
gion, Tanzania. KIDH is the national centre of
excellence for clinical management of drug resistant TB
in the country and has a bed capacity of 320. The hos-
pital provides TB services to more than 150 and 500 pa-
tients with drug resistant and susceptible TB per year,
respectively. Recruitment and sputa collections from
study participants were done at KIDH. Xpert® MTB/Rif
assay, smear microscopy for acid-fast-bacilli (AFB) and
isolation of MTBC on Lowenstein-Jensen (LJ) solid
medium was performed at KIDH Mycobacteriology la-
boratory. MTBC isolates were transported to the Central
Tuberculosis Reference Laboratory (CTRL) located at
Muhimbili National Hospital (MNH) in Dar-es-salaam,
Tanzania, for phenotypic susceptibility testing (DST) to
first- and second-line anti-TB drugs like RIF, INH, EMB,
SM, ofloxacin (OFX) and Kanamycin/Amikacin (KAN/
AMK) and DNA extraction. Due to its complexity, PZA-
DST is not routinely performed in Tanzania. MTBC
DNA were shipped to London School of Hygiene and
Tropical Medicine (LSHTM) for WGS and bioinformat-
ics analysis.
Study design, population and recruitment of participants
This study involved 57 and 30 participants who har-
boured M. tuberculosis that were resistant and suscep-
tible to anti-TB drugs respectively, presenting at KIDH
during the study period in 2014. Participants with resist-
ant isolates were recruited if they had laboratory results
by either GeneXpert MTB/RIF or phenotypic culture
and DST [16]. The drug resistance was either mono/
polyresistance-resistant or MDR-TB. The rest were re-
cruited if they were infected with MTB that was suscep-
tible to RIF by Xpert® MTB/Rif assay. Eligibility included
age ≥18 years, and willingness to sign a written informed
consent and provide sputum samples for laboratory
analysis. Very sick participants were excluded from the
study.
Data collection
A standardized semi-structured questionnaire containing
a set of study variables was used to collect data from
study participants and medical charts were used to
monitor treatment. Pre-treatment data that was col-
lected included clinical information such as symptoms
and signs suggestive of pulmonary tuberculosis (PTB),
any previous history of TB treatment, HIV status, abso-
lute CD4 + T cell count, the body mass index as the ratio
of weight (kg) and (height)2 (m2) and socio-demographic
characteristics such as age and gender. MDR-TB was
treated for at least 20 months and monitored monthly
with culture and smear microscopy for AFB while DS
TB was monitored with smear microscopy only to deter-
mine microbiological treatment response and program-
matic outcomes. WGS was performed on baseline
MTBC isolates.
Laboratory procedures
Samples collection, culture of MTBC and phenotypic drug-
susceptibility testing
Each study participant provided approximately 4 mL of
one spot sputum samples for culture. The samples were
processed using the modified Petroff’s method [31].
Briefly, 4 mLs of sputum was added to 4 mLs of 4% so-
dium hydroxide (NaOH). The mixture was vortexed and
left to stand at room temperature for 15 min. Thereafter,
the volume of the mixture was adjusted to 50 mLs in a
falcon tube and concentrated by centrifugation at 3000 g
for 15 min. Supernatants were discarded into a container
with 25% phenol. Sediments were suspended in Phos-
phate buffer saline solution (PBS) before being inocu-
lated on LJ culture media as recommended by the
Clinical and Laboratory Standard Institute (CLSI) for TB
culture [22]. In summary, 200 μL of sputum sediments
were inoculated on two slopes of LJ medium containing
either pyruvate or glycerol. Culture and identification of
MTBC colonies were performed according to locally
existing and CLSI standard operating procedures.
Phenotypic drug susceptibility testing of the MTBC iso-
lates was performed using a standard proportion method
on LJ media [53, 54].
DNA extraction and whole genome sequencing
Genomic DNA was extracted at Muhimbili University of
Health and Allied Sciences (MUHAS) using a modified
protocol based on Restriction Fragment Length Poly-
morphism (RFLP) developed at the National Institute for
Public Health and the Environment (RIVM), Bilthoven,
Netherlands [55]. The concentration and quality of the
DNA were measured using Qubit™ 4 Fluorometer (Invi-
trogen®). DNA samples were shipped to London School
of Hygiene and Tropical Medicine (LSHTM), United
Kingdom for whole genome sequencing. The DNA were
shipped in screw capped cryo-vials and sealed with par-
afilm materials. During shipment the DNA were packed
in double box and transported in iced packed with insu-
lators materials in a thermo-stable shipping box where
the Styrofoam was at least 1.5 in. thick. Library prepar-
ation, cluster amplification and sequencing were per-
formed according to the manufacturer’s instructions
Katale et al. BMC Genomics          (2020) 21:174 Page 11 of 15
(QIAGEN). The QIAseq FX DNA Library Kit (QIAGEN)
was used for library preparation according to the manu-
facturer’s protocol. The QIAseq FX DNA Library Kit
covers DNA fragmentation for 15 min, adapter ligation
and a final purification of the samples using AMPure XP
beads (Beckman-Coulter). Library DNA content was
analysed using a Qubit 3.0 fluorometer. The sizes of
DNA fragments were quantified using the Agilent High
Sensitivity DNA Kit (Agilent Technologies) on an
Agilent 2100 Bioanalyser (Agilent Genomics) according
to the manufacturer’s protocol. Samples were pooled to
create pools of libraries at a concentration between 10
and 12pM, and loaded into the MiSeq® using MiSeq® v2
Reagent Kit. WGS was performed at the LSHTM using
MiseqTM Sequencing 172 System MiSeqV2–500 cycles
(Illumina), producing paired-end sequence reads of 151
bp.
Bioinformatics and genomic data analysis
Quality control and mapping of reads
Initial quality control (QC) reads were characterized
using Kraken version v1.1 to exclude contamination and
low-quality reads bases of less than 20 Qscore (defined
as -10log10 (P), where P is the probability of an error as
determined by the sequencing platform). Quality reads
were mapped to the H37Rv reference genome
(AL123456) using BWA mem [56] with default settings.
The median depth and the percentage of the reference
covered by a minimum of 10 reads were calculated using
SAMtools depth [56] and custom scripts. Samples with
sufficient amounts of MTBC data were used for down-
stream analysis.
Variant calling and in-silico resistance and lineage typing
Variants in drug resistance gene candidates were called
using LoFreq version v2.1.2 [57]. These were annotated
and compared to the TBProfiler database [58] (http://
tbdr.lshtm.ac.uk/) as it does not perform its own variant
calling but annotates existing calls as drug resistance
mutations using a database of mutations. Additionally,
large indels were identified by looking at depth in candi-
date genes. The coverage across lineage specific markers
was inspected using htsbox (https://github.com/lh3/
htsbox) and custom scripts to assign specific lineages to
the isolates.
Phylogeny reconstruction
Variants throughout the whole genome were called
using SAMtools/BCFtools version v1.9 [59]. The result-
ing variant call format (VCF) files were collated together
filtering was performed. In short, sites in samples were
marked as missing if less than 5 reads aligned to a
position and monomorphic sites or those with greater
than 10% missing data were removed. Using all SNPs, a
maximum likelihood phylogeny was constructed using
ExaML version v3.0.21, a state of the art tool for phylo-
genomic analyses [60]. The phylogenetic reconstruction
was used in conjunction with lineage predictions output
by TBProfiler. These predictions were based on the
universally adopted lineage nomenclature and SNP bar-
code reported by Coll et al. [61]. This was visualized
with drug resistance phenotypes and lineages using
iTOL [62]. The lineages were assigned based on the
SNP barcode available at doi:https://doi.org/10.1038/
ncomms5812 and has been adopted as the standard for
Mtb WGS data.
Analysis of clinical data
Descriptive statistics was performed for demographic
characteristics, frequency and distribution of mutation
patterns in MDR-TB and other resistance patterns in
MTBC. A Pearson chi-square test was used to determine
the association between age, gender, HIV status and
CD4 counts if applicable, Body mass index (BMI), his-
tory of previous TB treatment and genotype drug resist-
ance as the main outcome using STATA version 14
(StataCorp LP, College Station, TX, USA). A p-value of
< 0.05 considered statistically significant. Genotype drug
resistance was defined as any mutations that are known
to confer decreased anti tuberculosis drug susceptibility.
Skewed data, Student’s -test and Wilcoxon rank-sum
tests were used for normally distributed data. The body
weight based on BMI values for both adults was catego-
rized into two groups namely; thinness (≤ 18.5) and nor-
mal> 18.5 as recommended by the World Health
Organization (WHO). Kappa statistics (K) were used to
determine agreement between drug susceptibility testing
(DST) and genetic drug resistance using four levels of
agreement for kappa: < 0.40 (poor), 0.40–0.59 (fair),
0.60–0.80 (good), and > 0.80 (excellent) [63].
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